» Articles » PMID: 38575308

45 Activates SHP2 Through Inhibition of Oxidative Stress to Regulate Osteoblast and Osteoclast Differentiation

Overview
Specialty Geriatrics
Date 2024 Apr 4
PMID 38575308
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of this study is to observe LP45 ( 45) to investigate the mechanism by which LP45 attenuates oxidative stress-induced damage and regulates the osteoblast-osteoclast balance.

Materials And Methods: The oxidative stress level and osteoblast- and osteoclast-related proteins were detected by immunofluorescence staining, Western blotting, ROS fluorescent probe and ELISA. Osteoblast cell proliferation capacity was determined by the CCK-8 assay. X-ray observation and HE staining were used to detect the effect of LP45 on osteoporosis.

Results: The expression level of SHP2 and Src was significantly increased, and the expression levels of NOX4, P22, P47, IL-1β, NLRP3, IRF3, RANK, β-catenin and INF-β were inhibited in LP45 group and LPS + LP45 group as compared to those in LPS group. Compared with that in LPS group, the concentration of SOD was increased and the concentration of MDA was decreased in LPS + LP45 group. The protein expressions of OPG, RANKL, RUNX3, RANK and β-catenin in LP45 group and LPS + LP45 group increased. The protein expressions of NF-κB, CREB and AP-1 in LP45 group and LPS + LP45 group decreased significantly. The results were also confirmed by immunofluorescence staining and ROS fluorescent probe. X-ray observation and HE staining showed that LP45 could inhibit the progression of osteoporosis.

Conclusion: LP45 can exert its antioxidant effect by inhibiting the production of oxidative stress to activate the SHP2 signaling pathway, thus promoting osteoblast differentiation and repressing osteoclast formation to maintain bone homeostasis and improve bone metabolism.

References
1.
Brown J, Don-Wauchope A, Douville P, Albert C, Vasikaran S . Current use of bone turnover markers in the management of osteoporosis. Clin Biochem. 2022; 109-110:1-10. DOI: 10.1016/j.clinbiochem.2022.09.002. View

2.
Park M, Cha H, Kim J, Kim J, Yang H, Yoon S . NOX4 promotes ferroptosis of astrocytes by oxidative stress-induced lipid peroxidation via the impairment of mitochondrial metabolism in Alzheimer's diseases. Redox Biol. 2021; 41:101947. PMC: 8027773. DOI: 10.1016/j.redox.2021.101947. View

3.
Bauler T, Kamiya N, Lapinski P, Langewisch E, Mishina Y, Wilkinson J . Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations. Dis Model Mech. 2010; 4(2):228-39. PMC: 3046097. DOI: 10.1242/dmm.006130. View

4.
Agidigbi T, Kim C . Reactive Oxygen Species in Osteoclast Differentiation and Possible Pharmaceutical Targets of ROS-Mediated Osteoclast Diseases. Int J Mol Sci. 2019; 20(14). PMC: 6678498. DOI: 10.3390/ijms20143576. View

5.
Wang T, Yu X, He C . Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte. Curr Drug Targets. 2018; 20(1):1-15. DOI: 10.2174/1389450119666180405094046. View